| Size | Price | Stock | Qty |
|---|---|---|---|
| 100mg |
|
||
| 250mg |
|
||
| 500mg |
|
| ln Vitro |
In immortalized mouse proximal tubule cells (mPTC), MnTBAP chloride (pretreatment with 1.14 μM before 10 ng/mL TGF-β1) diminished α-α expression and partially but significantly reversed E-cadherin decrease. -Induction of vimentin and SMA [1]. MnTBAP chloride (50 μM; 6 h) did not alter BMPR-II protein expression in HUVECs throughout a 16-hour time course, although it did raise BMPR-II mRNA 1.3-fold at 2 h. Smad 1/5 is phosphorylated more when MnTBAP chloride is present, suggesting that the BMP signaling pathway is regulated [2].
|
|---|---|
| ln Vivo |
In 5/6 Nx mice, MnTBAP chloride (10 mg/kg; i.p.; three times weekly for 12 weeks) decreases renal fibrosis [1].
|
| Animal Protocol |
Animal/Disease Models: C57BL/6J mice with 5/6 nephrectomy (Nx)[1]
Doses: 10 mg/kg Route of Administration: IP; three times per week for twelve weeks Experimental Results: Attenuated renal fibrosis in 5/6 Nx mice and decreased protein expressions of fibronectin, collagen III in remnant kidneys. |
| References |
| Exact Mass |
878.098
|
|---|---|
| CAS # |
55266-18-7
|
| Appearance |
Brown to black solid powder
|
| LogP |
3.42
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month Note: Please store this product in a sealed and protected environment, avoid exposure to moisture. |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~100 mg/mL (~113.75 mM)
0.5 M NaOH : 20 mg/mL (~22.75 mM) 1M NaOH : 10 mg/mL (~11.37 mM) |
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 4.17 mg/mL (4.74 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 4.17 mg/mL (4.74 mM) (saturation unknown) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 41.7 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly. Preparation of 20% SBE-β-CD in Saline (4°C，1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution. (Please use freshly prepared in vivo formulations for optimal results.) |
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
